Agios (AGIO) Q1 Loss Wider Than Expected, Revenues Miss
Zacks Investment Research | May 07, 2018 03:28AM ET
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) posted first-quarter 2018 loss of $1.63 per share, wider than the Zacks Consensus Estimate of a loss of $1.60 and the year-ago loss of $1.56.
Total revenues in the reported quarter amounted to $8.8 million, which lagged the Zacks Consensus Estimate of $14 million. Revenues plunged 16.2% from the year-ago figure of $10.5 million due to the adoption of the new revenue recognition standard.
The stock has outperformed the industry year to date, having surged 42.6% compared with the industry’s rally of 3.1%.
Research & development expenses were up 24.7% year over year to $78.2 million, largely driven by start-up costs for the AG-348 pivotal program in PK deficiency, including the initiation of the ACTIVATE-T trial, initiation of a phase I dose-escalation study of AG-270, the first-in-class MAT2A inhibitor, and IND enabling activities for AG-636, the DHODH inhibitor.
General and administrative expenses increased 66.2% year over year to $24.6 million due to higher costs due to growth in the company’s United States’ commercial organization to support the expected launch of Tibs0vo (ivosidenib) in the third quarter of 2018.
Pipeline Update
During the quarter, the FDA accepted on a priority review basis and set an action date of Aug 21, 2018 for the new drug application (NDA) for Tibsovo for the treatment of patients with R/R AML with an isocitrate dehydrogenase-1 (IDH1) mutation. The company plans to submit a Marketing Authorization Application to the European Medicines Agency for Tibsovo for R/R AML and an IDH1 mutation in the fourth quarter of 2018.
The company also initiated a phase I dose-escalation study for AG-270, a first-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor, in patients with methylthioadenosine phosphorylase (MTAP)-deleted tumors. It also initiated ACTIVATE-T, a single-arm pivotal trial for AG-348, in adult pyruvate kinase deficiency patients who receive regular blood transfusions.
The company plans to submit an investigational new drug application for its latest development candidate, AG-636, an inhibitor of the metabolic enzyme dihydroorotate dehydrogenase for the treatment of hematologic malignancies in the fourth quarter of 2018.
The company also plans to initiate a phase II proof of concept trial of AG-348 in thalassemia in the fourth quarter of 2018.
Get The News You Want
Zacks Rank & Stocks to Consider
Agios is a Zacks Rank #3 (Hold) stock.
A few better-ranked stocks from the same space worth considering are Ligand Pharmaceuticals (NASDAQ:LGND) , Protagonist Therapeutics (NASDAQ:PTGX) and Illumina, Inc. (NASDAQ:ILMN) . All of them sport a Zacks Rank #1 (Strong Buy). You can see .
Ligand’s earnings per share estimates have moved up from $4.24 to $4.43 for 2018 over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 15.2% year to date.
Protagonist’s loss estimates narrowed from $1.30 to 66 cents for 2018 and from $1.99 to $1.26 for 2019, over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.95%.
Illumina’s earnings per share estimates have moved up $4.59 to $4.84 for 2018 and from $5.33 to $5.57 for 2019, in the last 60 days. The company came up with a positive earnings surprise in all the preceding four quarters, with an average beat of 23.17%. The stock has rallied 16.4% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.